A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin

Inclusion Criteria: * Male or postmenopausal female. * Age 22-55 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 18.5 and 30.0 kilogram/meter per square (kg/m\^2) (both inclusive) at screening. * Considered eligible and generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Use of prescription or non-prescription medicinal products, including herbal medications, within 14 days before screening. Occasional use of over-the-counter vitamins, or paracetamol or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain is permitted. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Orthostatic hypotension, defined as a decrease in systolic blood pressure greater than or equal to 20 millimetres of mercury (mmHg) or a decrease in diastolic blood pressure greater than or equal to 10 (mmHg) from supine to standing after 3 minutes, at the screening visit. * Any laboratory safety parameters at screening outside the below laboratory ranges for: * Alanine Aminotransferase (ALT) greater than (\>) Upper normal limits (UNL) plus (+) 10 Percentage (%) * Aspartate Aminotransferase (AST) \> Upper limit normal (ULN) +20% * Bilirubin \> ULN + 20% * Creatinine \> ULN + 10%